(Q43824283)

English

A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).

scientific article published in November 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Gradishar WJ

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Stephenson P

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Glover DJ

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Neuberg DS

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Moore MR

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Windschitl HE

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Piel I

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Abeloff MD

8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

0 references

publication date

1 November 2001

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

2517-2522

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Cisplatin as first-line therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

A more general role for WR-2721 in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Ototoxicity of low- and moderate-dose cisplatin

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Peripheral sensory neuropathy and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Cysteine Protection against X Irradiation

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Phase I trials of WR-2721 and cis-platinum

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Clinical trials of WR-2721 and cis-platinum

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Phase I/II trials of WR-2721 and cis-platinum

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2517%3A%3AAID-CNCR1602%3E3.0.CO%3B2-Z

21 January 2018

Identifiers

10.1002/1097-0142(20011115)92:10<2517::AID-CNCR1602>3.0.CO;2-Z

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43824283&oldid=2103675132"